Clinically, activation of the PI3K/Akt pathway is not a benign event; it serves as a notable risk factor for earlier tumor recurrence and is consistently associated with a more aggressive tumor phenotype and poor patient prognosis 17. The gene discussed is AKT1; the disease is neoplasm.